Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Stimolazione a Corrente Alternata ad Alta Intensità come Terapia di Neuromodulazione per il Disturbo da Uso di Alcol: Uno Studio Pilota (HITACS-AUD)

12 ottobre 2026 aggiornato da: Shanghai Mental Health Center

This one-arm pilot study aims to evaluate the preliminary clinical, behavioral, and neurophysiological effects of high-intensity transcranial alternating current stimulation (HI-tACS) in individuals with alcohol use disorder (AUD). Participants will receive HI-tACS and undergo clinical and neurophysiological assessments before and after the intervention.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Alcohol use disorder (AUD) has become a major social and public health problem. Persistent alcohol craving, impaired self-control, and abnormalities in decision-making and inhibitory control are important clinical and cognitive features of AUD. High-intensity transcranial alternating current stimulation (HI-tACS) is a non-invasive neuromodulation approach that may have potential therapeutic effects in individuals with AUD. However, its clinical and neurobiological effects in AUD remain unclear. The investigators hypothesize that HI-tACS may reduce alcohol craving and improve self-regulation and cognitive-control functions in individuals with AUD. This one-arm pilot study aims to evaluate the preliminary effects and tolerability of a 2-week course of HI-tACS, using clinical assessments together with electroencephalographic, and magnetic resonance imaging measures to explore potential changes in craving, self-control, risky decision-making, inhibitory control, and related neural activity. This study may provide preliminary clinical and mechanistic evidence for the further development of HI-tACS as a potential intervention for AUD.

Tipo di studio

Interventistico

Iscrizione (Stimato)

18

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Shanghai, Cina
        • Reclutamento
        • Shanghai Mental Health Center
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 60 anni (Adulto)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Education level of junior high school or above, capable of completing questionnaires and behavioral tests;
  • Aged 18-60 years;
  • Meet DSM-5 diagnostic criteria for Alcohol Use Disorder;
  • No abnormal findings on physical examination;
  • Agree to participate in follow-up assessments;
  • No contraindications for MRI scanning.

Exclusion criteria:

  • Have impaired intelligence (Intelligence Quotient<70);
  • Prior tDCS or TMS treatment within the past 3 months;
  • Contraindications for TMS therapy (e.g., intracranial metal implants, history of traumatic brain injury, skull defects, cardiac pacemakers, cardiovascular diseases, or epilepsy);
  • Severe somatic diseases or major organ dysfunction;
  • Psychiatric disorders per DSM-5 criteria (e.g., schizophrenia, schizoaffective disorder, intellectual disability, autism spectrum disorder, dementia, memory impairment, or other cognitive disorders).
  • Psychiatric disorders per DSM-5 criteria (e.g., schizophrenia, schizoaffective disorder, intellectual disability, autism spectrum disorder, dementia, memory impairment, or other cognitive disorders).
  • Diagnosis of other substance-related and addictive disorders or behavioral addictions.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: HI-tACS

A 40-minute 15mA transcranial alternating current stimulus intervention with 77.5 Hz of real stimulus is conducted twice a day (at least 3 hours apart) for a total of 10 days in the intervention group of AUD.

A 40-minute 15mA transcranial alternating current stimulus intervention with 77.5 Hz of real stimulus is conducted twice a day (at least 3 hours apart) for a total of 10 days in the intervention group of AUD.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The change of alcohol craving
Lasso di tempo: Baseline, immediately after completion of the 2-week intervention

Alcohol craving will be measured by the alcohol craving Visual Analog Scale (VAS). The total score of VAS ranged from 0 to 10, in which higher scores mean a higher level of alcohol craving.

Baseline, immediately after completion of the 2-week intervention

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The change of drinking urge
Lasso di tempo: Baseline, immediately after completion of the 2-week intervention

Alcohol urge will be assessed using the Alcohol Urge Questionnaire (AUQ). The total score of AUQ ranges from 8 to 56, with higher scores indicating stronger urges to consume alcohol.

Baseline, immediately after completion of the 2-week intervention
Change of the compulsive drinking behavior
Lasso di tempo: Baseline, immediately after completion of the 2-week intervention

Compulsive drinking behavior will be measured by the short form of the Obsessive-Compulsive Drinking Scale (OCDS). The total score of OCDS ranges from 0 to 40, with higher scores reflecting greater obsessive-compulsive thoughts and behaviors related to alcohol use.

Baseline, immediately after completion of the 2-week intervention
Side effects of the modulation
Lasso di tempo: Immediately after each of the 20 HI-tACS sessions during the 2-week intervention period

Side effects will be assessed using a standardized adverse reaction evaluation form. The presence and severity of stimulation-related adverse reactions will be recorded for each symptom.

Immediately after each of the 20 HI-tACS sessions during the 2-week intervention period
Change of depressive symptoms.
Lasso di tempo: Baseline, immediately after completion of the 2-week intervention

Depressive symptoms will be measured using the 17-item Hamilton Depression Rating Scale (HAMD-17). The total score ranges from 0 to 52, with higher scores indicating more severe depressive symptoms.

Baseline, immediately after completion of the 2-week intervention
Change of anxiety symptoms
Lasso di tempo: Baseline, immediately after completion of the 2-week intervention

Anxiety symptoms will be assessed using the 14-item Hamilton Anxiety Rating Scale (HAMA-14). The total score ranges from 0 to 56, where higher scores reflect greater anxiety severity.

Baseline, immediately after completion of the 2-week intervention
Change of the self-control ability
Lasso di tempo: Baseline, immediately after completion of the 2-week intervention

Self-control ability will be measured using the Self-Control Scale (SCS). The total score ranges from 19 to 95, with higher scores of SCS indicating better self-regulation and impulse control.

Baseline, immediately after completion of the 2-week intervention
Change of the risky decision-making performance
Lasso di tempo: Baseline, immediately after completion of the 2-week intervention

Risky decision-making will be assessed using the Balloon Analogue Risk Task (BART), with task performance and concurrent electroencephalography (EEG) measures related to risk-taking, decision-making, and outcome processing recorded. In addition, the Pig Dice Game will be administered during functional magnetic resonance imaging (fMRI) to assess risk-taking decision-making and associated task-related brain activity. Behavioral and neuroimaging measures derived from these tasks will be used to characterize changes in risk-related decision-making.

Baseline, immediately after completion of the 2-week intervention
Change of the inhibitory control performance
Lasso di tempo: Baseline, immediately after completion of the 2-week intervention

Inhibitory control will be assessed using the Stop-Signal Task (SST), with task performance evaluated together with concurrent electroencephalography (EEG) measures related to response inhibition and inhibitory control.

Baseline, immediately after completion of the 2-week intervention
Change of the resting state neural activity.
Lasso di tempo: Baseline, immediately after completion of the 2-week intervention

Resting-state functional magnetic resonance imaging (rsfMRI) will be used to assess intrinsic brain activity and functional connectivity. Resting-state electroencephalography (rsEEG) will be employed to assess spontaneous neural oscillatory activity.

Baseline, immediately after completion of the 2-week intervention

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Individualized Electric Field Simulation
Lasso di tempo: Baseline, immediately after completion of the 2-week intervention

Individualized head models will be constructed using structural magnetic resonance imaging (sMRI), including T1-weighted imaging and diffusion tensor imaging (DTI). The electric field induced by HI-tACS will be simulated to characterize its spatial distribution and interindividual variability in modeled stimulation exposure.

Baseline, immediately after completion of the 2-week intervention
Change of the molecular-level neurochemistry
Lasso di tempo: Baseline, immediately after completion of the 2-week intervention

SPICE magnetic resonance spectroscopic imaging will be used to explore changes in brain neurochemical profiles following HI-tACS. Metabolite-related signals and their spatial distributions will be assessed to characterize potential intervention-associated neurochemical alterations. Individual metabolite measurements will be analyzed separately, with their respective quantification methods and measurement units reported.

Baseline, immediately after completion of the 2-week intervention

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

11 ottobre 2026

Completamento primario (Stimato)

30 novembre 2026

Completamento dello studio (Stimato)

31 dicembre 2026

Date di iscrizione allo studio

Primo inviato

10 novembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

10 novembre 2025

Primo Inserito (Effettivo)

12 novembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • JDu-016

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Sì

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .